We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Predictors Evaluated for Microalbuminuria in Type 2 Diabetes

By LabMedica International staff writers
Posted on 12 Mar 2020
Print article
Image: The Gen‐S hematology analyzer provides a complete blood count, a five-part differential leukocyte count, and a reticulocyte count (Photo courtesy of InCav).
Image: The Gen‐S hematology analyzer provides a complete blood count, a five-part differential leukocyte count, and a reticulocyte count (Photo courtesy of InCav).
Chronic inflammation has an important role in the development and progression of type 2 diabetes through immunologic inflammatory mechanisms. The neutrophil‐to‐lymphocyte ratio (NLR) is a new, simple, and inexpensive marker of subclinical inflammation and has been used as a systemic inflammatory marker in chronic diseases.

A symptom of nephropathy is albuminuria usually initiating with microalbuminuria, which was found to be a marker of vascular endothelial damage. Albuminuria is a well‐known predictor of poor renal outcomes in patients with type 2 diabetes and in essential hypertension and as such, it is important to monitor and diagnose in order to treat early.

A team of medical scientists working with the Ziv Medical Center (Safed, Israel) included in their study the data from 168 patients with type 2 diabetes mellitus (DM), which included patients aged ≥40 years old who had type 2 DM for at least four years. Patients were classified into three groups according to glycated hemoglobin (HbA1c) and microalbuminuria: Group A were patients with controlled diabetes; Group B were patients with uncontrolled diabetes (both groups without microalbuminuria); and Group C, were patients with uncontrolled diabetes with microalbuminuria.

The team examined the patients records regarding plasma glucose, HbA1c, creatinine, albumin, total cholesterol, triglycerides (TG), high‐density lipoprotein (HDL), and low‐density lipoprotein (LDL) levels in the venous blood samples obtained in the morning after 8‐hours fasting. Complete blood counts were analyzed in the hematology unit with a Beckman‐Coulter Gen‐S hematology analyzer (Beckman Coulter Inc., Brea, CA, USA). Mean platelet volume (MPV) and red blood cell distribution width (RDW) levels were gathered from patients' complete blood count, and NLR was calculated as the ratio of absolute number of neutrophil and lymphocyte counts.

The scientists reported that a significant difference in NLR was found between Group C and groups A and B. A statistically significant difference in RDW was found between groups B and C. Receiver operating characteristic curve analysis of inflammatory markers and microalbuminuria prediction showed an area under curve (AUC) of 0.675 for NLR and 0.614 for RDW. NLR value of 2.54 has 39.7% sensitivity, 78.8% specificity, and 45% positive predictive value (PPV). RDW value of 14.44% has 37.9% sensitivity, 76% specificity, and 41.5% PPV. TG/HDL ratio was lower in patients with controlled diabetes (group A) compared to the other two groups. Serum creatinine was higher as was the ratio to microalbumin in group C compared to the other two study groups.

The authors concluded that high levels of NLR were found in diabetic patients with microalbuminuria compared to controlled and uncontrolled patients without microalbuminuria. At the same time, they found high RDW values in patients with diabetes with microalbuminuria compared to diabetic patients without microalbuminuria. The study was published on February 25, 2020 in the Journal of Clinical Laboratory Analysis.

Related Links:
Ziv Medical Center
Beckman Coulter Inc


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Creatine Kinase-MB Assay
CK-MB Test
New
Nutating Mixer
Enduro MiniMix

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.